- Home
- RNAZ vs ADXN Comparison
RNAZ vs ADXN Comparison
Compare RNAZ & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- ADXN
- Stock Information
- Founded
- RNAZ 2016
- ADXN 2002
- Country
- RNAZ United States
- ADXN Switzerland
- Employees
- RNAZ N/A
- ADXN N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- ADXN Health Care
- Exchange
- RNAZ Nasdaq
- ADXN Nasdaq
- Market Cap
- RNAZ 8.7M
- ADXN 8.5M
- IPO Year
- RNAZ 2021
- ADXN N/A
- Fundamental
- Price
- RNAZ $13.77
- ADXN $9.60
- Analyst Decision
- RNAZ Strong Buy
- ADXN
- Analyst Count
- RNAZ 1
- ADXN 0
- Target Price
- RNAZ $280.00
- ADXN N/A
- AVG Volume (30 Days)
- RNAZ 421.5K
- ADXN 24.3K
- Earning Date
- RNAZ 11-13-2025
- ADXN 11-21-2025
- Dividend Yield
- RNAZ N/A
- ADXN N/A
- EPS Growth
- RNAZ N/A
- ADXN N/A
- EPS
- RNAZ N/A
- ADXN N/A
- Revenue
- RNAZ N/A
- ADXN $210,347.00
- Revenue This Year
- RNAZ N/A
- ADXN $86.57
- Revenue Next Year
- RNAZ N/A
- ADXN N/A
- P/E Ratio
- RNAZ N/A
- ADXN N/A
- Revenue Growth
- RNAZ N/A
- ADXN N/A
- 52 Week Low
- RNAZ $6.15
- ADXN $6.51
- 52 Week High
- RNAZ $643.94
- ADXN $12.05
- Technical
- Relative Strength Index (RSI)
- RNAZ 55.86
- ADXN 53.29
- Support Level
- RNAZ $12.11
- ADXN $8.67
- Resistance Level
- RNAZ $15.49
- ADXN $10.55
- Average True Range (ATR)
- RNAZ 1.74
- ADXN 0.81
- MACD
- RNAZ -0.13
- ADXN 0.02
- Stochastic Oscillator
- RNAZ 23.76
- ADXN 31.30
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.